Jacobson K
Oregon Research Group, Eugene 97401.
J Antimicrob Chemother. 1993 Mar;31 Suppl C:121-9. doi: 10.1093/jac/31.suppl_c.121.
In a double-blind, double-dummy, multicentre study the efficacy and safety of dirithromycin 500 mg/day given orally once daily for 10-14 days were compared with those of erythromycin 1000 mg/day given orally four times daily for 10-14 days in patients with bacterial pneumonia. At 3-5 days post-therapy, 90 dirithromycin- and 83 erythromycin-treated patients were evaluable; the main reason for non-evaluability was failure to isolate the causative organism. Symptomatic responses were favourable in 94.5% of dirithromycin- and 100% of erythromycin-treated patients at post-therapy. At late post-therapy (2-3 weeks after completion of treatment), symptomatic responses were favourable in 98.7% of dirithromycin- and 94.8% of erythromycin-treated patients. At post-therapy, 63.3% of dirithromycin- and 50.6% of erythromycin-treated patients were unable to be evaluated bacteriologically, mainly due to Mycoplasma pneumoniae or Legionella pneumophila being assessed serologically. In the remaining evaluable patients treated with dirithromycin and erythromycin, bacteriological responses were favourable in 91.4% and 87.8%, respectively. At late post-therapy, favourable bacteriological responses occurred in 89.7% and 86.8%, respectively, of dirithromycin- and erythromycin-treated patients. Abdominal pain was the only treatment-emergent event to occur significantly more frequently in dirithromycin-treated patients.
在一项双盲、双模拟、多中心研究中，对10 - 14天内每日口服一次500毫克地红霉素的疗效和安全性与10 - 14天内每日口服四次1000毫克红霉素在细菌性肺炎患者中的疗效和安全性进行了比较。治疗后3 - 5天，90例接受地红霉素治疗和83例接受红霉素治疗的患者可进行评估；不可评估的主要原因是未能分离出致病微生物。治疗后，94.5%接受地红霉素治疗的患者和100%接受红霉素治疗的患者症状反应良好。在治疗后期（治疗结束后2 - 3周），98.7%接受地红霉素治疗的患者和94.8%接受红霉素治疗的患者症状反应良好。治疗后，63.3%接受地红霉素治疗的患者和50.6%接受红霉素治疗的患者无法进行细菌学评估，主要是因为肺炎支原体或嗜肺军团菌采用血清学评估。在其余可评估的接受地红霉素和红霉素治疗的患者中，细菌学反应良好的分别为91.4%和87.8%。在治疗后期，接受地红霉素和红霉素治疗的患者中，细菌学反应良好的分别为89.7%和86.8%。腹痛是唯一在地红霉素治疗患者中显著更频繁出现的治疗中出现的事件。
